Laggard: Prevail Therapeutics Inc. (NASDAQ:PRVL)

New York-based Prevail Therapeutics (NASDAQ:PRVL) Prevail is a gene therapy company founded in 2017 that focuses on developing disease-modifying AAV-based gene therapies for neurodegenerative diseases by applying a precision medicine approach.

The company’s lead compound PR001 is being evaluated for Parkinson’s disease with GBA1 mutation and neuronopathic Gaucher disease. The FDA has given its nod for its IND filing. It intends to initiate a Phase 1/2 trial for PR001 in neuronopathic Gaucher disease in 2019.

The insider ownership percentage is the key indicator, can be used by investors, to measure the outlook of senior management has on their company. Institutional ownership refers to the ownership stake in a company that is held by large financial organizations, pension funds or endowments.

Insider trading is the buying or selling of any publicly traded company’s stock and this can be done by someone who has non-public, material information about that PRVL. Insider trading can be illegal or legal depending on when the insider makes the trade. It is illegal when the material information is still non-public.


Institutional ownership is the amount of a Prevail Therapeutics Inc. (NASDAQ:PRVL)’s available stock owned by mutual or pension funds, insurance companies, investment firms, private foundations, endowments or other large entities that actually manage the funds on the behalf of others, so its an interesting element for the traders to note it.

a Healthcare sector firm, Prevail Therapeutics Inc. (NASDAQ:PRVL) stock slumped -14.85% on Monday and when day-trade ended the stock finally concluded at $11.24 and number of shares that changed hands during the day are 613831. The number of shares PRVL stock currently held by all its shareholders are 38.64 and floated shares, the number of shares are available for trading in an open market on last trading day are 27.39. The average volume of shares for 3 months is 585.22 and PRVL stock value has moved between $12.09 – 16.78 in last one year.

The Gross margin is the difference between the revenue and the cost of goods sold (COGS), divided by revenue. In other words, Gross Margin is a percentage value, while Gross Profit is a monetary value. The stock has gained -17.35% in 2019 to date.

The higher the volatility, the riskier the security. For example, when the stock market rises and falls more than one percent over a sustained period of time, it is called a “volatile” market, if the stock price stays relatively stable, the security has low volatility. The Prevail Therapeutics Inc. (NASDAQ:PRVL) weekly volatility is measured as 15.52%.

The price to cash per share ration is 4.33.

The current share price indicates that stock is -33.49% away from its one year high and is moving -6.72% ahead of its 52-week low. PRVL’s distance from 20 day simple moving average is -22.87% and distance from 50-Day simple moving average is -22.87%.

Leave a Reply